AstraZeneca (AZN) PT Set at GBX 4,550 by UBS Group
AstraZeneca (LON:AZN) received a GBX 4,550 ($60.84) price target from equities research analysts at UBS Group in a research report issued on Monday, www.boersen-zeitung.de reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s target price indicates a potential downside of 12.57% from the company’s current price.
Several other analysts also recently weighed in on the stock. Barclays set a GBX 6,300 ($84.24) target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, September 13th. Goldman Sachs Group reissued a “sell” rating and set a GBX 3,800 ($50.81) target price on shares of AstraZeneca in a research report on Tuesday, October 17th. Citigroup set a GBX 6,000 ($80.22) target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, September 13th. Bryan, Garnier & Co raised shares of AstraZeneca to a “buy” rating and boosted their target price for the stock from GBX 4,700 ($62.84) to GBX 5,380 ($71.93) in a research report on Monday, September 11th. Finally, reissued a “reduce” rating and set a GBX 4,100 ($54.82) target price on shares of AstraZeneca in a research report on Monday, September 11th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of GBX 5,200.82 ($69.54).
AstraZeneca (LON AZN) opened at GBX 5,204 ($69.58) on Monday. The company has a market cap of $65,800.00 and a P/E ratio of 2,526.21. AstraZeneca has a 52 week low of GBX 4,136.50 ($55.31) and a 52 week high of GBX 5,520 ($73.81).
ILLEGAL ACTIVITY NOTICE: “AstraZeneca (AZN) PT Set at GBX 4,550 by UBS Group” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/astrazeneca-azn-pt-set-at-gbx-4550-by-ubs-group/1798479.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with Analyst Ratings Network's FREE daily email newsletter.